Inclusion and Exclusion Criteria
This review is inclusive of all research articles presenting original data that reported infectious complications of mTOR inhibitors (sirolimus/rapamycin or everolimus) in the treatment of VAs. We did not restrict inclusion based on the year of publication. For inclusion, patients reported in the study had to have (1) been diagnosed with a VA, (2) received sirolimus or everolimus, and (3) had a reported infectious complication. Exclusion criteria included articles that (1) did not report original data (e.g. review articles and commentaries), (2) did not report infections, (3) were not available in English, or (4) were abstracts, trial protocols, or dissertations. We included studies of both children and adults with VAs.